Melphalan Sun (Melphalan)

Melphalan belongs to the alkylating agent class. It forms covalent bonds with the N7 position of guanine in DNA, creating cross‑links that block DNA replication and transcription. This damage triggers cell‑cycle arrest and apoptosis, especially in rapidly dividing cancer cells.

The specific dose of Melphalan Sun is determined by the prescribing oncologist based on the patient’s diagnosis, disease stage, body surface area and overall health. Dosing regimens are individualized and should follow the prescriber’s written order.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Melphalan shares the DNA‑cross‑linking mechanism of other alkylating agents such as cyclophosphamide, but it has a higher potency and is often used in high‑dose protocols for specific cancers like multiple myeloma. Its toxicity profile, especially myelosuppression, may be more pronounced, requiring careful monitoring.

Melphalan Sun should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Melphalan Sun is administered intravenously by a qualified healthcare professional. The infusion is typically given over a set period, often as a short infusion or as part of a high‑dose regimen, depending on the treatment protocol prescribed by the oncologist.

The most serious risks include severe myelosuppression leading to infection or bleeding, secondary malignancies, pulmonary fibrosis, and renal toxicity. Patients should be monitored closely for signs of infection, lung symptoms, and changes in kidney function throughout therapy.

Melphalan Sun should not be used in patients with known hypersensitivity to melphalan or other alkylating agents, in pregnant or nursing women, and in individuals with severe renal or hepatic impairment unless the benefits clearly outweigh the risks. It is also contraindicated in patients receiving live vaccines.